Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting

Rhea-AI Summary

Hemogenyx Pharmaceuticals has reported that all resolutions were passed at its Annual General Meeting on June 30, 2022. Key resolutions included the adoption of the 2021 Annual Report, approval of the Directors' Remuneration Policy, and reappointment of the Company’s auditor. Notably, the resolution for the Directors' Remuneration Policy had 84.7% votes in favor, while the Employee Incentive Plan garnered 97.9% approval. The total issued share capital as of June 28, 2022, was 979,749,321 shares. Full voting details are available via the National Storage Mechanism.

Positive

• 98.99% of votes supported the reappointment of the auditor.
• 99.77% of votes approved the 2021 Annual Report.
• The Employee Incentive Plan received 97.90% approval.

Negative

• Only 84.70% of votes supported the Directors' Remuneration Policy.
• 15.30% of votes were against the Directors' Remuneration Policy.

LONDON, ENGLAND / ACCESSWIRE / June 30, 2022 / Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To adopt the 2021 Annual Report and Accounts​	48,304,030	99.77	110,911	0.23	48,414,941	4.94	190,357
2. To approve the Directors' Remuneration Policy​	40,993,480	84.70	7,402,314	15.30	48,395,794	4.94	209,504
3. To reappoint the Company's auditor	47,905,435	98.99	490,359	1.01	48,395,794	4.94	209,504
4.​ To authorise the Audit Committee to determine the auditor's remuneration​	47,894,585	98.93	518,814	1.07	48,413,399	4.94	191,899
5. To approve the Employee Incentive Plan with Non-Employee Sub-Plan	47,475,011	97.90	1,018,002	2.10	48,493,013	4.95	112,285
6. To authorise the Directors to allot equity securities​	47,367,119	97.90	1,016,191	2.10	48,383,310	4.94	221,988
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
7. To disapply pre-emption provisions​	47,476,822	97.90	1,016,191	2.10	48,493,013	4.95	112,285
8. To reduce the notice period for general meetings	47,938,029	99.01	476,912	0.99	48,414,941	4.94	190,357

1. The Company's issued share capital ("ISC") on 28 June 2022, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 979,749,321 ordinary shares.
2. A ‘vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/707201/Hemogenyx-Pharmaceuticals-PLC-Announces-Result-of-Annual-General-Meeting

FAQ

What were the outcomes of the Annual General Meeting for HOPHF?

All resolutions were passed at the AGM held on June 30, 2022.

How many votes were cast for the Directors' Remuneration Policy for HOPHF?

40,993,480 votes were cast in favor, constituting 84.70%.

What percentage of votes supported the adoption of the 2021 Annual Report for HOPHF?

The adoption received 99.77% of votes in favor.

What was the total issued share capital of HOPHF as of June 28, 2022?

The total issued share capital was 979,749,321 ordinary shares.